Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2024-07-09 Report Publication Anno…
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Einladung zum H1 2024-Webcast von Cosmo am 24. Juli 2024
Report Publication Announcement Classification · 98% confidence The document is a press release dated July 9, 2024, announcing the upcoming publication of the 'Halbjahres-Resultate 2024' (Half-Year Results 2024) on July 24, 2024. It explicitly invites participants to a live video webcast presentation to discuss the financial and operational results. Crucially, it states that the 'Medienmitteilung' (Press Release) and the 'Halbjahresbericht 2024' (Half-Year Report 2024) will be available for download on July 24, 2024. Since this document is an announcement about the release of the actual report, and it is short (3602 chars), it fits the definition of a Report Publication Announcement (RPA) according to Rule 2 ('MENU VS MEAL' rule). The content is focused on scheduling the release and the subsequent conference call, not presenting the full interim report itself.
2024-07-09 German
Cosmo shareholders approved all resolutions proposed by the Board of Directors at Extraordinary General Meeting
AGM Information Classification · 99% confidence The document explicitly discusses the results of an 'Extraordinary General Meeting' (EGM) where shareholders approved several resolutions, including a dividend distribution and the adoption of FY2023 annual accounts. The key focus is on the outcomes of a shareholder vote at a general meeting. This aligns directly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions AGM-related topics (like approving accounts and remuneration policy), the event itself is an EGM, and the content is the result announcement, making DVA the most precise fit over AGM-R (which is for presentations/materials *at* the AGM) or DEF 14A (which is remuneration focused). The document is a press release announcing the results, not the detailed voting report itself, but DVA covers the announcement of voting results.
2024-07-05 English
Aktionärinnen und Aktionäre von Cosmo genehmigten an der ausserordentlichen Generalversammlung alle vom Verwaltungsrat vorgeschlagenen Traktanden
AGM Information Classification · 99% confidence The document is a press release detailing the outcomes of an 'ausserordentliche Generalversammlung' (Extraordinary General Meeting - EGM). Key outcomes mentioned are the approval of the dividend distribution, the approval of the 2023 annual financial statements, and the approval of the remuneration policy update. Since the document reports the official results of shareholder votes on various resolutions presented at a general meeting, it directly relates to the voting outcomes of that meeting. The most specific category for reporting official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it mentions the approval of the annual financial statements (which might suggest 10-K or AR), the primary focus and context is the meeting's resolutions and outcomes, making DVA the best fit. It is not a full 10-K or AR, but a summary of the meeting's decisions.
2024-07-05 German
Cosmo’s oral diagnostic drug Lumeblue® receives approval of New Drug Application in China
Regulatory Filings Classification · 100% confidence The document is a press release dated June 18, 2024, announcing that Cosmo's partner, CMS, received approval from the NMPA in China for the drug Lumeblue®. It details the significance of the drug, market potential, and includes company/product background information. Crucially, it contains an 'Upcoming Calendar of Events' listing an 'Extraordinary General Meeting' and 'Half Year Results 2024'. The presence of an announcement regarding an upcoming EGM suggests this document is related to corporate governance or shareholder matters, but the primary content is a business/product update. Since it is a formal announcement of a significant business event (drug approval) and not a regulatory filing form (like 10-K or MRQ), nor a transcript (CT) or a dedicated financial report (IR/ER), it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a standard press release. Given the options, and that it is a formal announcement of a material event, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it shares characteristics with an Earnings Release (ER) in terms of being a periodic update, but it is not explicitly reporting financial results for a period. Since it is a press release announcing a major operational milestone, RNS is the best fit as a general regulatory/material event disclosure.
2024-06-18 English
Das orale Diagnostikum Lumeblue® von Cosmo erhält Zulassung als neues Medikament in China
Regulatory Filings Classification · 100% confidence The document is a press release from Cosmo Pharmaceuticals N.V. announcing that its partner, China Medical System Holdings Limited (CMS), received drug registration approval from the NMPA in China for the oral diagnostic Lumeblue®. The text details the significance of the market, clinical trial results, and provides company/partner overviews. Crucially, it includes a 'Finanzkalender' listing an 'Ausserordentliche Generalversammlung' (Extraordinary General Meeting) on July 5, 2024, and a 'Halbjahresbericht 2024' (Half-Year Report 2024) on July 24, 2024. The content itself is an announcement of a regulatory/commercial milestone, not the full financial report (10-K or IR) or a transcript (CT). Since it is a press release announcing significant corporate news (drug approval and partnership update) and does not fit neatly into specific financial reporting categories like 10-K, IR, or ER, it is best classified as a general Regulatory Filing (RNS) or potentially an announcement related to corporate activity. Given the nature of the announcement (regulatory approval and partnership update), RNS is the most appropriate general regulatory category, although it shares characteristics with an Earnings Release (ER) in terms of timing announcements, the core subject is regulatory approval, not financial results highlights. Since it is a formal announcement of a significant event, RNS is the best fit among the provided options, as it is a general regulatory announcement.
2024-06-18 German
Cosmo to bring real-time AI into intelligent medical devices with NVIDIA IGX
Regulatory Filings Classification · 100% confidence The document is a press release dated June 3, 2024, announcing a strategic technological update regarding the GI Genius platform integrating the NVIDIA IGX platform, scheduled for Q3 2024 availability. It contains quotes from the CEO and President, company background, and an upcoming calendar of events. This format—a news announcement detailing operational or product developments, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general press announcement. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, it best fits the 'Earnings Release' category, which often covers key operational highlights and near-term outlook, even if it's not strictly tied to quarterly results (the next results are scheduled for July 24, 2024). Given the content focuses on a major product/technology update, ER is the most appropriate fit among the provided options for a significant, non-mandated corporate announcement.
2024-06-03 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.